Temporarily increased TGFβ following radon spa correlates with reduced pain while serum IL-18 is a general predictive marker for pain sensitivity.
Chronic painful musculoskeletal disease
IL-18
Joints
Radon spa
Spine
TGFβ
Journal
Radiation and environmental biophysics
ISSN: 1432-2099
Titre abrégé: Radiat Environ Biophys
Pays: Germany
ID NLM: 0415677
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
30
04
2018
accepted:
12
11
2018
pubmed:
21
11
2018
medline:
11
4
2020
entrez:
21
11
2018
Statut:
ppublish
Résumé
Sustained pain relief following radon spa therapy in patients suffering from chronic painful diseases has been well described. But still, the underlying mechanisms are not fully understood. We conducted the prospective and explorative RAD-ON01 study which included 103 patients who suffered from chronic painful musculoskeletal disorders of the spine and/or joints and present here the data of the examination of pro- and anti-inflammatory cytokines in the serum of the patients before and at weeks 6, 12 and 30 after therapy. While TNFα, IL-1β, IFNγ, IL-1Ra and IL-10 were not altered, TGFβ was temporarily significantly (p = 0.013) elevated 6 weeks after therapy. Importantly, this elevation positively correlated with lowered pain sensitivity (r = 0.41). Further, the amount of IL-18 in the serum positively correlated with lowered pain sensitivity. Therefore, IL-18 can be considered as predictive marker for pain sensitivity of radon spa patients. We conclude that alterations in TGFβ and general IL-18 levels in serum have prognostic and predictive value in situations of lowered pain by exposure of patients to very low-doses of radiation as it is the case in radon spa.
Identifiants
pubmed: 30456560
doi: 10.1007/s00411-018-0768-z
pii: 10.1007/s00411-018-0768-z
doi:
Substances chimiques
Biomarkers
0
Interleukin-18
0
Transforming Growth Factor beta
0
Radon
Q74S4N8N1G
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-135Références
Rheumatol Int. 2018 Mar;38(3):353-362
pubmed: 29327104
Rheumatol Int. 2005 Apr;25(3):205-10
pubmed: 14673618
Toxicol Res (Camb). 2015 Aug 11;5(1):12-33
pubmed: 30090323
Cold Spring Harb Perspect Biol. 2011 Jan 01;3(1):a003277
pubmed: 20810549
Rheumatology (Oxford). 2000 Aug;39(8):894-902
pubmed: 10952746
Autoimmunity. 2009 May;42(4):337-9
pubmed: 19811294
Radiother Oncol. 1999 Jun;51(3):197-203
pubmed: 10435813
Front Oncol. 2012 Sep 25;2:120
pubmed: 23057008
Autoimmunity. 2017 Mar;50(2):133-140
pubmed: 28263099
Z Gerontol Geriatr. 2019 Mar;52(2):164-171
pubmed: 29368066
Mod Rheumatol. 2019 Jan;29(1):165-172
pubmed: 29451048
Rheumatol Int. 2013 Nov;33(11):2839-50
pubmed: 23864139
Clin Rheumatol. 2016 Nov;35(11):2783-2788
pubmed: 27053095
Autoimmunity. 2009 May;42(4):340-2
pubmed: 19811295
Clin Exp Immunol. 2015 Jan;179(1):50-61
pubmed: 24730395
Am J Phys Med Rehabil. 2017 Jan;96(1):e9-e10
pubmed: 27196383
Front Immunol. 2017 May 03;8:519
pubmed: 28515727
Mol Pain. 2018 Jan-Dec;14:1744806918757286
pubmed: 29353540
Strahlenther Onkol. 2015 Sep;191(9):742-9
pubmed: 26051282
J Cell Sci. 2017 Dec 1;130(23):3955-3963
pubmed: 29196474
Radiat Environ Biophys. 2015 Mar;54(1):123-136
pubmed: 25274266
Int J Mol Sci. 2016 Aug 11;17(8):
pubmed: 27529227
Front Immunol. 2018 Sep 18;9:1834
pubmed: 30279685
J Exp Med. 2002 Jun 3;195(11):1499-505
pubmed: 12045248
Cancer Lett. 2015 Nov 28;368(2):230-7
pubmed: 25888451
Front Immunol. 2017 Jul 25;8:882
pubmed: 28791026
Int J Biometeorol. 2018 Feb;62(2):195-205
pubmed: 28884308
Health Phys. 2016 Aug;111(2):212-7
pubmed: 27356067
Int J Biometeorol. 2016 Aug;60(8):1287-301
pubmed: 26607275
Arthritis Res Ther. 2016 Dec 1;18(1):279
pubmed: 27906049
Immunity. 2000 Oct;13(4):443-51
pubmed: 11070163
Adv Exp Med Biol. 2013;990:49-60
pubmed: 23378002
Int J Radiat Biol. 2007 Jun;83(6):357-66
pubmed: 17487675
Nat Rev Rheumatol. 2018 Mar;14(3):146-156
pubmed: 29323344
Autoimmunity. 2013 Aug;46(5):323-8
pubmed: 23215648